ATRA was capable of decreasing Pin1 and tumor growth in APL mouse models and APL human patients’ bone marrow, along with in vivo models of triple negative breast cancer [149] and acute myeloid leukemia [150]; both cancers overexpress Pin1. This evidence concerns the gene PIN1 and acute myeloid leukemia.